

SEP 02 2003

Sheet 1 of 5

Form PTO-1449	ATTY DOCKET NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu	GROUP 63	

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AM	6,399,663	06/04/02	Haces et al.	514	642	
	6,387,395	05/14/02	Eppstein et al.	424	450	
	6,376,248	04/23/02	Hawley-Nelson et al.	435	458	
	6,214,804	04/10/01	Felgner et al.	514	44	
	6,110,916	08/29/00	Haces et al.	514	252.11	
	6,110,662	08/29/00	Foung et al.	435	5	
	6,086,913	07/11/00	Tam et al.	424	450	
	6,051,429	04/18/00	Hawley-Nelson et al.	435	458	
	6,020,202	02/01/00	Jessee	435	458	
	5,948,925	09/07/99	Keynes et al.	552	540	
	5,948,767	09/07/99	Scheule et al.	514	44	
	5,935,936	08/10/99	Fasbender et al.	514	44	
	5,908,777	06/01/99	Lee et al.	435	320	
	5,908,635	06/01/99	Thierry	424	450	
	5,906,922	05/25/99	Whittaker et al.	435	69.1	
	5,869,606	02/09/99	Whittaker	530	345	
	5,854,224	12/29/98	Lockett et al.	514	44	
	5,840,710	11/24/98	Lee et al.	514	44	
	5,834,439	11/10/98	Haces et al.	514	42	
	5,830,878	11/03/98	Gorman et al.	514	44	
	5,830,430	11/03/98	Unger et al.	424	1.21	
	5,827,703	10/27/98	Debs et al.	435	172.3	
	5,795,587	08/18/98	Gao et al.	424	450	
	5,785,992	07/28/98	Ansell et al.	424	450	
	5,783,565	07/21/98	Lee et al.	514	44	
	5,780,053	07/14/98	Ashley et al.	424	450	
	5,753,613	05/19/98	Ansell et al.	514	2	
	5,744,335	04/28/98	Wolff et al.	435	172.3	
	5,736,392	04/07/98	Hawley-Nelson et al.	435	320.1	
	5,719,131	02/17/98	Harris et al.	514	44	
	5,703,055	12/30/97	Felgner et al.	514	44	
	5,693,509	12/02/97	Cotten et al.	435	172.3	
	5,674,908	10/07/97	Haces et al.	514	642	
	5,650,096	07/22/97	Harris et al.	252	357	
	5,627,159	05/06/97	Shih et al.	514	44	
	5,595,897	01/21/97	Midoux et al.	435	172.3	
V	5,589,466	12/31/96	Felgner et al.	514	44	

EXAMINER *Andi Manschet*DATE CONSIDERED *11/28/03*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 02 2003

Sheet 2 of 5

Form PTO-1449	ATTY DOCKET NO. 45-93A	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu et al.		GROUP 1631	

Am	5,583,198	12/10/96	Whittaker	530	345	
	5,578,475	07/12/94	Jessee	435	172.3	
	5,550,289	08/27/96	Eppstein et al.	564	293	
	5,545,412	08/13/96	Eppstein et al.	424	450	
	5,512,291	05/28/96	Curiel et al.	530	391.7	
	5,459,127	10/17/95	Felgner et al.	514	7	
	5,455,335	10/03/95	Kahne et al.	536	5	
	5,334,761	08/02/94	Gebeyehu et al.	564	197	
	5,283,185	02/01/94	Epan et al.	435	172.3	
	5,279,833	01/18/94	Rose	424	450	
	5,165,925	11/24/92	Leong	424	88	
	4,235,871	11/25/80	Papahadjopoulos et al.	424	19	
	3,152,188	10/06/64	Kirkpatrick et al.	260	584	
	2,901,461	08/25/59	Auerbach et al.	260	47	
	2003-0069173	04/10/03	Hawley-Nelson et al.	514	8	
	2002-0156049	10/24/02	Haces et al.	514	79	
	2002-0086849	07/04/02	Gebeyehu et al.	514	44	
✓	2002-0077305	06/20/02	Jessee et al.	514	44	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes/No
Am	WO 02/34879	05/02/02	PCT	C12N	_____	
	WO 00/27795	05/18/00	PCT	C07C 211/64	_____	
	WO 00/58488	10/05/00	PCT	C12N 15/87	_____	
	WO 99/29712	06/17/99	PCT	C07K 5/02	_____	
	WO 99/02190	01/21/99	PCT	A61K 48/00	_____	
	WO 98/40502	09/17/98	PCT	C12N 15/64	_____	
	WO 98/29541	07/09/98	PCT	C12N 15/00	_____	
	WO 98/02190	01/22/98	PCT	A61K 47/48	_____	
	WO 97/42819	11/20/97	PCT	A01N 37/18	_____	
	WO 96/40961	12/19/96	PCT	C12N 15/88	_____	
	WO 95/02698	01/26/95	PCT	C12N 15/88	_____	
	WO 95/17373	06/29/95	PCT	C07C 211/63	_____	
	WO 94/27435	12/08/94	PCT	A01N 25/26	_____	
	WO 91/17424	11/14/91	PCT	G01N 21/00	_____	
	WO 90/11092	10/04/90	PCT	A61K 48/00	_____	
	0 846 680 A1	06/10/98	EP	C07C 279/12	_____	
✓	1,567,214	05/16/69	FR	C12N	_____	

EXAMINER

A. Mansueti

DATE CONSIDERED

11/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 02 2003

Sheet 3 of 5

Form PTO-144	ATTY DCKET NO. 45-934	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebreyesus		GROUP 1631	

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

AM		Behr, J-P. (Sept. 1994), "Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy," <i>Bioconjug. Chem.</i> 5:382-389
		Bottinger, M. et al. (1988), "Condensation of vector DNA by the chromosomal protein HMGI results in efficient transfection," <i>Biochim. Biophys. Acta</i> 950:221-228
		Cotten, M. and Wagner, E. (Dec. 1993), "Non-viral approaches to gene therapy," <i>Curr. Opin. Biotechnol.</i> 4:705-710
		Giles, R.V. (2000), "Antisense oligonucleotide technology: From EST to therapeutics," <i>Curr. Opin. Mol. Therap.</i> 2:238-252
		Henkel und Cie. G.m.b.H. (April 1970), abstract no. 68522p, "Low-foaming detergents containing bisquaternary compounds," <i>Chem. Abst.</i> 72(14):116
		Kaneda, Y. et al. (1989), "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver," <i>Science</i> 243:375-378
		Murphy, A.L. (Jan. 1999), "Catch VP22: the hitch-hiker's ride to gene therapy?" <i>Gene Therapy</i> 6:4-5
		Neckers, L.M. (May 1993), "Cellular Internalization of Oligodeoxynucleotides," in <i>Antisense Research and Applications</i> , Crooke, S.T. and Leblue, B., eds., CRC Press, LLC, Boca Raton, FL, pp. 451-460
		Neurath, et al. (1990), "B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides," <i>J. Gen. Virol.</i> 71:85-95
		Rothenberg, M. et al. (1989), "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications," <i>J. Natl. Can. Inst.</i> 81:1539-1544
		van der Krol, A.R. et al. (1988), "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," <i>Biotechniques</i> 6:958-976
		Wixon, H.E. (1969), "Anionic detergents containing trialkylamine oxides as fabric softeners," <i>Chem. Abstracts</i> , Vol. 72, Abstract No. 68523q, p. 116
V		(Jan. 1993) <i>Sigma Catalog</i> , pp. 1028-1034

EXAMINER

Andin Mansueti

DATE CONSIDERED

11-28-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	ATTY DOCKET NO. 45,93A-1	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu	GROUP 1631		

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes/No
AM	WO 93/14778	08/05/93	PCT	A61K 37/00	—	
↓	WO 93/05162	03/18/93	PCT	C12N 15/63	—	
	WO 93/03709	03/04/93	PCT	A61K 9/127	—	

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

AM	Bennett, C.F. et al. (1992), "Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides," Mol. Pharm. 41:1023-1033
↓	Bond, V.C. and Wold, B. (June 1987), "Poly-L-Ornithine-Mediated Transformation of Mammalian Cells," Mol. Cell. Biol. 7(6):2286-2293
↓	Chaney, W.G. et al. (1986), "High-Frequency Transfection of CHO Cells Using Polybrene," Som. Cell Mol. Genet. 12(3):237-244
↓	Dong, Y. et al. (1993), "Efficient DNA transfection of quiescent mammalian cells using poly-L-ornithine," Nucl. Acids Res. 21:771-772
↓	Donnelly-Roberts, D.L. and Lentz, T.L. (1991), "Structural and conformational similarity between synthetic peptides of curare-mimetic neurotoxins and rabies virus glycoprotein," Mol. Brain Res. 11:107-113
↓	Duzgunes, N. and Felgner, P. (1993), "Intracellular Delivery of Nucleic Acids and Transcription Factors by Cationic Liposomes," Meth. Enzymol. 221:303-317
↓	Farhood, H. et al. (1992), "Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity," Biochim. Biophys. Acta 1111:239-246
↓	Felgner, P.L. et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," Genetically Targeted Research & Therapies: Antisense and Gene Therapy, S306, p. 206
AM	Felgner, P.L. and Holm, M. (Spring 1989), "Cationic Liposome-Mediated Transfection," Focus 11(2):21-25
↓	Felgner, P.L. (1993), "Cationic Lipid/Polynucleotide Condensates for In Vitro and In Vivo Polynucleotide Delivery - The Cytofectins," J. Liposome Res. 3(1):3-16
↓	Gao, X. and Huang, L. (1993), "Cationic Liposomes and Polymers for Gene Transfer," J. Liposome Res. 3(1):17-30
↓	Gao, X. and Huang, L. (1993), "Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes," Nucl. Acids Res. 21(12):2867-2872
AM	Huang, L. and Zhou, F. (1992), "Liposome and Immunoliposome Mediated Delivery of Proteins and Peptides," Targeting of Drugs 3 - The Challenge of

No pull.
date

EXAMINER

Adin Masaly

DATE CONSIDERED

11-28-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	ATTY DOCKET NO. 45-93A	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Geber		GROUP 637	

from prev. page

			Peptides and Proteins , Gregoriadis, G. and Florence, A.T. (eds.), Plenum Press, New York, NY, pp. 45-50
AM			Litzinger, D.C. and Huang, L. (1992), "Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen," <i>Biochim. Biophys. Acta</i> 1127 :249-254
			Litzinger, D.C. and Huang, L. (1992), "Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications," <i>Biochim. Biophys. Acta</i> 1113 :201-227
			Nabel, G.J. and Felgner, P.L. (May 1993), "Direct gene transfer for immunotherapy and immunization," <i>Tibtech</i> 11 :211-215
			Nair, S. et al. (1992), "Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines," <i>J. Immun. Meth.</i> 152 :237-243
			Park, Y.S. and Huang, L. (1992), "Interaction of synthetic glycopospholipids with phospholipid bilayer membranes," <i>Biochim Biophys. Acta</i> 1112 :251-258
			Park, Y.S. et al. (1992), "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo," <i>Biochim. Biophys. Acta</i> 1108 :257-260
			Stegmann, T. et al. (1989), "Protein-Mediated Membrane Fusion," <i>Ann. Rev. Biophys. Chem.</i> 18 :187-211
			Stewart, M.J. et al. (1992), "Gene Transfer In Vivo with DNA-Liposome Complexes: Safety and Acute Toxicity in Mice," <i>Human Gene Therapy</i> 3 :267-275
			Trubetskoy, V.S. et al. (1992), "Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells," <i>Biochim. Biophys. Acta</i> 1131 :311-313
			Trubetskoy, V.S. et al. (1992), "Use of N-Terminal Modified Poly(L-lysine)-Antibody Conjugate as a Carrier for Targeted Gene Delivery in Mouse Lung Endothelial Cells," <i>Bioconjugate Chem.</i> 3 :323-327
			White, J.M. (1989), "Cell-to-cell fusion," <i>Cell. Biol.</i> 1 :934-939
			White, J.M. (1990), "Viral and Cellular Membrane Fusion Proteins," <i>Ann. Rev. Physiol.</i> 52 :675-697
✓			Zhou, X. and Huang, L. (1992), "Targeted delivery of DNA by liposomes and polymers," <i>J. Controlled Release</i> 19 :269-74

EXAMINER

Ardin Mandel

DATE CONSIDERED

11-28-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.